{"id":6258,"date":"2021-03-09T21:19:44","date_gmt":"2021-03-10T05:19:44","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=6258"},"modified":"2021-03-09T21:19:44","modified_gmt":"2021-03-10T05:19:44","slug":"safety-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-bbv152-interim-results-from-a-double-blind-randomised-multicentre-phase-2-trial-and-3-month-follow-up-of-a-double-blind-randomised","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/09\/safety-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-bbv152-interim-results-from-a-double-blind-randomised-multicentre-phase-2-trial-and-3-month-follow-up-of-a-double-blind-randomised\/","title":{"rendered":"Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBV152: Interim Results from a Double-Blind, Randomised, Multicentre, Phase 2 Trial, and 3-Month Follow-up of a Double-Blind, Randomised Phase 1 Trial"},"content":{"rendered":"<ul>\n<li>Interim results from a double-blind randomized phase 2 trial (n=380) of the Bharat Biotech whole-virion inactivated SARS-CoV-2 vaccine (BBV152) show robust neutralizing titers against wild-type SARS-CoV-2 at day 56 following two doses administered on day 0 and day 28. In a plaque-reduction neutralization test, the 6 \u00b5g dose group compared to the 3 \u00b5g dose group had higher geometric mean neutralizing titers (197 vs 100) and higher proportion of seroconversion (98% vs 93%) at day 56. No significant difference was observed in the proportion of participants who reported local or systematic adverse reactions between the dose groups (20% vs 21%), and no serious adverse events were reported in the study.<\/li>\n<\/ul>\n<p><i>Ella et al.\u00a0(Mar 8, 2021). Safety and Immunogenicity of an Inactivated SARS-CoV-2 Vaccine, BBV152: Interim Results from a Double-Blind, Randomised, Multicentre, Phase 2 Trial, and 3-Month Follow-up of a Double-Blind, Randomised Phase 1 Trial. The Lancet Infectious Diseases. <\/i><a href=\"https:\/\/doi.org\/10.1016\/S1473-3099(21)00070-0\">https:\/\/doi.org\/10.1016\/S1473-3099(21)00070-0<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Interim results from a double-blind randomized phase 2 trial (n=380) of the Bharat Biotech whole-virion inactivated SARS-CoV-2 vaccine (BBV152) show robust neutralizing titers against wild-type SARS-CoV-2 at day 56 following two doses administered on day 0 and day 28. In a plaque-reduction neutralization test, the 6 \u00b5g dose group compared to the 3 \u00b5g dose&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/03\/09\/safety-and-immunogenicity-of-an-inactivated-sars-cov-2-vaccine-bbv152-interim-results-from-a-double-blind-randomised-multicentre-phase-2-trial-and-3-month-follow-up-of-a-double-blind-randomised\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[33],"topic":[31],"class_list":["post-6258","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-vaccines","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6258","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=6258"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6258\/revisions"}],"predecessor-version":[{"id":6259,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/6258\/revisions\/6259"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=6258"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=6258"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=6258"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=6258"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}